| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.BOR.0000127594.92432.7C |
| P698 | PubMed publication ID | 15201602 |
| P2093 | author name string | Carol Dukes Hamilton | |
| P433 | issue | 4 | |
| P304 | page(s) | 393-398 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Current Opinion in Rheumatology | Q15750473 |
| P1476 | title | Infectious complications of treatment with biologic agents | |
| P478 | volume | 16 |
| Q46986955 | A case of recurrent breast cancer with life-threatening multiple lung metastasis markedly responding to CMF as third-line chemotherapy |
| Q37445355 | A case of tuberculous arthritis following the use of etanercept |
| Q44836776 | A postoperative infectious complication in a patient with rheumatoid arthritis treated with adalimumab |
| Q37286386 | Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. |
| Q81354761 | Advances in psoriasis treatment |
| Q35019838 | Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis |
| Q48205734 | Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor |
| Q37131025 | From conventional to cutting edge: the new era of biologics in treatment of psoriasis |
| Q36328708 | Immunosuppression related to collagen-vascular disease or its treatment |
| Q44836771 | Incidence of tuberculosis disease and latent tuberculosis infection in patients with end stage renal disease in an endemic region |
| Q80488259 | Infection of an urachal cyst during etanercept therapy in juvenile idiopathic arthritis |
| Q24677051 | Interleukin-23 drives innate and T cell-mediated intestinal inflammation |
| Q39684886 | Managing Inflammatory Manifestations in Patients with Chronic Granulomatous Disease |
| Q44997280 | Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase |
| Q37590270 | Pharmacovigilance of biopharmaceuticals: challenges remain |
| Q38195802 | Progressive disseminated histoplasmosis in the HIV population in Europe in the HAART era. Case report and literature review. |
| Q36160669 | Rheumatoid arthritis: an overview of new and emerging therapies |
| Q84128746 | Search for Mycobacterium leprae in wild mammals |
| Q39430057 | Severe cutaneous and arthritic psoriasis in patient with AIDS: a good outcome with therapy using etanercept |
| Q43859359 | Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents |
| Q38360672 | Systematic review: Whipple's disease (Tropheryma whipplei infection) and its unmasking by tumour necrosis factor inhibitors |
| Q51574799 | TNF-alpha antagonist therapy modify the tuberculin skin test response. |
| Q33606744 | The potential of p38 MAPK inhibitors to modulate periodontal infections |
| Q38539281 | Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues |
| Q80413579 | Unusual manifestation of histoplasmosis in connective tissue diseases |
| Q34507149 | Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase |
| Q36516943 | Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients |
| Q34041797 | Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis |
| Q84600169 | [Biologic therapy and infections] |
| Q79949492 | [Off-label use of biologic agents in the treatment of dermatosis, Part 1: infliximab and adalimumab] |
| Q80516806 | [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] |
Search more.